{"doi":"10.12968/hosp.2002.63.2.2087","title":"Restoring post-prandial insulin release in type 2 diabetes","abstract":"<jats:p>Tight blood glucose control is a primary aim of type 2 diabetes treatment. Combining metformin with the amino acid derivative, nateglinide, tackles both beta cell dysfunction and insulin resistance, and produces a greater decrease in haemoglobin A1c levels than treatment with either drug alone.</jats:p>","journal":"Hospital Medicine","year":2002,"id":684722,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1390571,"name":"John Andrews","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Restoring post-prandial insulin release in type 2 diabetes","abstract":"<jats:p>Tight blood glucose control is a primary aim of type 2 diabetes treatment. Combining metformin with the amino acid derivative, nateglinide, tackles both beta cell dysfunction and insulin resistance, and produces a greater decrease in haemoglobin A1c levels than treatment with either drug alone.</jats:p>","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"11902096","pmcid":null,"openalex_id":"https://openalex.org/W2314283572","authors":[],"funders":[],"total_grants":0,"fwci":0.1094,"citation_percentile":0.47336804,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.magonlinelibrary.com/doi/pdf/10.12968/hosp.2002.63.2.2087","host_type":"publisher"},{"url":"https://doi.org/10.12968/hosp.2002.63.2.2087","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/11902096","host_type":"repository"}],"fields_of_study":["Metabolism, Diabetes, and Cancer","Diabetes Management and Research","Diabetes Treatment and Management"],"mesh_terms":["Nateglinide","Insulin Secretion","Blood Glucose","Clinical Trials as Topic","Cyclohexanes","Diabetes Mellitus, Type 2","Humans","Hypoglycemic Agents","Insulin","Metformin","Phenylalanine","Postprandial Period"],"keywords":["Medicine","Nateglinide","Type 2 diabetes","Metformin","Insulin resistance","Insulin","Internal medicine","Post-prandial","Diabetes mellitus","Endocrinology","Drug","Pharmacology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T14:52:55.553125Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}